PSNL Earnings

PSNL reported its earnings on 2026-05-07, showcasing a revenue of 15.47M against an estimate of 14.39M, resulting in a 7.52% surprise. The EPS was -0.29, surpassing the expected -0.23 by -26.09%. The stock experienced a -0.17% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PSNL's earnings announcement on 2026-05-07, the stock price moved by -0.17% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, PSNL's stock price tends to shift by an average of -0.99% in the 10 days leading up to earnings and 13.55% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate PSNL's annual revenue to reach 18.70M, while the EPS is projected at -0.25. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PSNL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PSNL's stock price typically moves by -0.99% in the 10 days before its earnings and 13.55% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.25 and revenue of 18.70M.

The earnings call summary reflects strong quarterly growth, with a 26% increase in tests and a clear focus on expanding clinical volumes. The company's confidence in their ultrasensitive testing approach and strategic partnerships, along with improving gross margins and aggressive reimbursement strategies, indicate positive market sentiment. Despite some unclear responses in the Q&A, the overall outlook remains optimistic, especially with upcoming presentations at ASCO and a growing biopharma backlog. These factors suggest a positive stock price movement over the next two weeks.